Santoni, Matteo; Maiorani, Giada; Faloppi, Luca; Di Nunno, Vincenzo; Gatto, Lidia; Massari, Francesco; Battelli, Nicola, Optimizing renal function and outcome of patients with cT2 renal cell carcinoma, «ANNALS OF TRANSLATIONAL MEDICINE», 2019, 7, Article number: S39 , pp. 1 - 3 [Scientific article]Open Access
Mollica V.; Di Nunno V.; Massari F., Pembrolizumab plus axitinib: A new treatment option for patients with metastatic renal cell carcinoma, «CHINESE CLINICAL ONCOLOGY», 2019, 8, Article number: 20190405 , pp. 1 - 4 [Scientific article]
Nunno V.D.; Mollica V.; Gatto L.; Santoni M.; Cosmai L.; Porta C.; Massari F., Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis, «IMMUNOTHERAPY», 2019, 11, pp. 631 - 643 [Scientific article]
Saeed O.; Lopez-Beltran A.; Fisher K.W.; Scarpelli M.; Montironi R.; Cimadamore A.; Massari F.; Santoni M.; Cheng L., RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications, «JOURNAL OF CLINICAL PATHOLOGY», 2019, 72, pp. 135 - 139 [Scientific article]
Massari F.; Di Nunno V.; Santoni M., Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417–27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?, «EUROPEAN UROLOGY ONCOLOGY», 2019, 2, pp. 340 - 341 [Scientific article]
Massari F.; Di Nunno V.; Santoni M.; Gatto L.; Mollica V.; Porta C., Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End, «EUROPEAN UROLOGY ONCOLOGY», 2019, 2, pp. 603 - 604 [Scientific article]
Santoni M.; Montironi R.; Battelli N.; Massari F., Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842–3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma, «EUROPEAN UROLOGY», 2019, 75, pp. 64 - 66 [Scientific article]
Mollica V.; Di Nunno V.; Gatto L.; Santoni M.; Scarpelli M.; Cimadamore A.; Lopez-Beltran A.; Cheng L.; Battelli N.; Montironi R.; Massari F., Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor, «CANCERS», 2019, 11, Article number: 830 , pp. 1 - 16 [Scientific article]Open Access
Prisciandaro M.; Ratta R.; Massari F.; Fornarini G.; Caponnetto S.; Iacovelli R.; De Giorgi U.; Facchini G.; Scagliarini S.; Sabbatini R.; Caserta C.; Peverelli G.; Mennitto A.; Verzoni E.; Procopio G., Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: Real-world data from an Italian managed access program, «AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS», 2019, 42, pp. 42 - 45 [Scientific article]
Santoni M.; Conti A.; Massari F.; Di Nunno V.; Faloppi L.; Galizia E.; Morbiducci J.; Piva F.; Buti S.; Iacovelli R.; Ferretti B.; Cimadamore A.; Scarpelli M.; Lopez-Beltran A.; Cheng L.; Battelli N.; Montironi R., Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies, «EXPERT REVIEW OF CARDIOVASCULAR THERAPY», 2019, 17, pp. 917 - 927 [Scientific article]
Iacovelli R.; Galli L.; De Giorgi U.; Porta C.; Nole F.; Zucali P.; Sabbatini R.; Mosca A.; Atzori F.; Santini D.; Facchini G.; Fornarini G.; Buti S.; Massari F.; Masini C.; Ricotta R.; Biasco E.; Lolli C.; Gri N.; Verri E.; Miggiano C.; Vitale M.G.; Tortora G., The effect of a treatment delay on outcome in metastatic renal cell carcinoma, «UROLOGIC ONCOLOGY», 2019, 37, pp. 529 - 535 [Scientific article]
Massari, F.; Mollica, V.; Di Nunno, V.; Gatto, L.; Santoni, M.; Scarpelli, M.; Cimadamore, A.; Lopez-Beltran, A.; Cheng, L.; Battelli, N.; Montironi, R.; Brandi, G., The human microbiota and prostate cancer: Friend or foe?, «CANCERS», 2019, 11, Article number: 459 , pp. 459 - 469 [Scientific article]Open Access
Massari F.; Di Nunno V.; Santoni M.; Gatto L.; Caserta C.; Morelli F.; Zafarana E.; Carrozza F.; Mosca A.; Mollica V.; Iacovelli R.; Sabbatini R.; Porta C.; Bracarda S., Toward a genome-based treatment landscape for renal cell carcinoma, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2019, 142, pp. 141 - 152 [Scientific article]
Mollica V, Di Nunno V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F, A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor., «ANTI-CANCER DRUGS», 2018, 29, pp. 911 - 913 [Scientific article]
Massari F.; Santoni M.; di Nunno V.; Cheng L.; Lopez-Beltran A.; Cimadamore A.; Gasparrini S.; Scarpelli M.; Battelli N.; Montironi R., Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies, «CANCER TREATMENT REVIEWS», 2018, 68, pp. 80 - 85 [Scientific article]
